Un-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Limited announced unaudited Q3 FY26 results (quarter ended Dec 31, 2025) on Feb 14, 2026. Standalone revenue from operations grew to about Rs 2,520 lakhs for the quarter (vs ~Rs 2,366 lakhs in Q3 FY25, roughly 6-7% YoY) and ~Rs 7,241 lakhs for nine months (vs ~Rs 6,573 lakhs, ~10% YoY). Quarterly profit after tax dropped sharply compared to the same quarter last year, while nine-month PAT appears higher year-on-year. Auditor Pundarikashyam and Associates issued an unmodified limited review report with no qualifications, going-concern flag, or emphasis of matter. Consolidated results include subsidiary Proton Remedies Pvt Ltd. The company also confirmed no deviation in use of ~Rs 13.36 crore raised via preferential issue in November 2025 and no defaults on loans or debt securities.
Mixed picture for shareholders — revenue growth is modest (under 10%) and Q3 profit came under pressure, but a clean audit, no debt defaults, and higher nine-month PAT offer some comfort. Near-term stock reaction is likely muted-to-negative until full-year numbers clarify the profit trend.